Healthcare Outlook
Dermatophytic Onychomycosis Treatment Market Growth Rate Analysis 2026
Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.
Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-sample/2053
Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis.
The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).
Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market
Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.
Development of new therapies that aid in treatment of dermatophytic onychomycosis is expected to drive growth of the dermatophytic onychomycosis treatment market over the forecast period
Introduction of new drug candidates and adoption of new treatment approaches is a major factor contributing to the dermatophytic onychomycosis treatment market growth. For instance, in 2014, the U.S. Food and Drug Administration (FDA) approved two new topical antifungal drugs—efinaconazole and tavaborole— for the treatment of dermatophytic onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole is the first approved topical triazole antifungal agent and tavaborole is the first approved oxobarole antifungal agent for this indication. These agents offer short treatment courses, high cure rates, and few relapse cases.
Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma.
Detailed Segmentation:
Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:
Systemic Therapy
Topical Therapy
Device-based Therapy
Global Dermatophytic Onychomycosis Treatment Market, By End User:
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
Global Dermatophytic Onychomycosis Treatment Market, By Geography:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/dermatophytic-onychomycosis-treatment-market-2053
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Tylosin Market: Checkout the Unexpected Future Growth
Tylosin is used in livestock for various purposes such as a feed additive for growth promotion and as an antibiotic against infectious diseases in animals such as chickens, turkeys, felines, canines, pigs, calves, and others. These antibiotics aid in the treatment of chronic respiratory disease (CRD) associated with Mycoplasma Gallisepticum and Mycolplasma synoviae and other infections.
Tylosin is used for treatment and control of swine dysentery associated with Brachyspira Hyodysenteriae and for the control of porcine proliferate enteropathies in pigs. Moreover, Tylosin is highly effective in tylosin-responsive diarrhea in dogs, which is a canine chronic, recurrent diarrhea that responds repeatedly to Tylosin treatment.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2061
Market Dynamics
The global Tylosin market is expected to witness significant growth over the forecast period, owing to rising demand for Tylosin in livestock industry. For instance, according to a study by Ministry for Primary Industries, New Zealand 2016, Tylosin accounted for over 83% of macrolide and lincosamide sales during 2011 and 2014 and the trend is expected to continue over the forecast period.
Moreover, certain mergers and acquisitions are expected to boost the market growth over the forecast period. For instance, Eily, Lilly, and Company acquired Novartis Animal Health in 2014. Varied product offering by manufacturers such as Elanco Animal Health is expected to propel the global Tylosin market growth over the forecast period. For instance, Elanco offers Component with Tylan, an implant line with initial and terminal implants for steers and heifers. This implant includes a tylosin tartrate (Tylan) pellet that dissolves and releases antibacterial throughout the implant site.
The global Tylosin market size was valued at US$ 379.0 million in 2017, and is expected to witness a CAGR of 1.2% over the forecast period (2018 – 2026).
Increasing demand for healthy livestock is expected to support growth of global Tylosin market over the forecast period
The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain the positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aide in providing healthy food products for consumption in humans.
Key players operating in the global Tylosin market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health.
Detailed Segmentation:
Global Tylosin Market, By Drug Type:
Tylosin Phosphate
Tylosin Tartrate
Others
Global Tylosin Market, By Application:
Felines
Canines
Livestock
Others
Global Tylosin Market, By Route Of Administration:
Oral
Injectable
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/tylosin-market-2061
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Hormone Replacement Therapy Market Anticipates Steady Growth Till 2026
New mergers and acquisitions is one of the major factor driving the growth of the hormone replacement therapy market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.
Robust pipeline is also expected to support growth of the hormone replacement therapy market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults.
The global hormone replacement therapy market size was valued at US$ 10.58 billion in 2017 and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2079
Increasing prevalence of various chronic conditions are expected to drive growth of the hormone replacement therapy market
Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market. According to the European Association of Urology: 2016 report, in middle-aged men, the incidence of hypogonadism varies from 2.1% to 12.8%. The incidence of low testosterone and symptoms of hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe. Ease in access and government support for research and development activities is expected to aid in growth of the hormone replacement therapy market. Financial help by NGOs such as the National Gaucher Society help patients receive enzyme replacement therapy that are costly.
Hormone Replacement Therapy Market - Regional Insights
On the basis of region, the global hormone replacement therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hormone replacement therapy market, owing to continuous launch of various generic products for hormone replacement therapies by manufacturers. Furthermore, Europe is expected to be the second largest contributor to the hormone replacement therapy market, in terms of revenue and is expected to gain significant traction in the near future. This is owing to launch of new drugs and therapies to combat secondary hyperparathyroidism and presence of significant population suffering from the disease in this region. For instance, in December 2016, Amgen’s drug etecalcetide (Parsabiv) received marketing approval in Europe by the European Commission for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney diseases.
Hormone Replacement Therapy Market - Competitive Landscape
Manufacturers are focusing on developing generic versions of various drugs for the treatment of certain disorders that are highly prevalent in women such as hypothyroidism. For instance, Teva Pharmaceutical Industries Ltd. launched generic version of Vagifem (estradiol vaginal inserts), 10 mcg in the U.S. on 24, July 2017. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.
Key players operating in the global hormone replacement therapy market include Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.
Detailed Segmentation:
Global Hormone Replacement Therapy Market, By Therapy Type:
Estrogen Replacement Therapy
Human Growth Hormone (HGH) Replacement Therapy
Thyroid Replacement Therapy
Testosterone Replacement Therapy
Global Hormone Replacement Therapy Market, By Route of Administration:
Oral
Parenteral
Others
Global Hormone Replacement Therapy Market, By Application:
Hypothyroidism
Male Hypogonadism
Growth Hormone Deficiency
Menopause
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/hormone-replacement-therapy-market-2079
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Ranitidine Market – Global Industry Insights to 2026
Healthcare professionals have been keenly interested in the treatment of gastroesophageal reflux disease (GERD) and stomach & intestinal ulcer owing to its increasing prevalence. GERD is common health problem, which leads to serious medical complications and further huge medical expense in its diagnosis and treatment. The two most frequently observed symptoms associated with GERD are heartburn and acid regurgitation. Usually, over-the-counter antacids, proton pump inhibitor, and H-2 receptor blockers are used to decrease the effects of stomach acids or to block acid production.
Ranitidine is a histamine H2 antagonists and available as both over-the-counter (OTC) and prescription drug, indicated in the treatment of gastroesophageal reflux disease (GERD). Ranitidine decreases the acid production from stomach for up to 12 hours. Also, ranitidine is commonly used in erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome. It could be taken orally or intravenously.
To Access the Free Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2131
The global ranitidine market size was valued at US$ 412.4 Mn in 2017, and is expected to witness a CAGR of 1.8% over the forecast period (2018 – 2026).
Growing Research and Development (R&D) on Ranitidine is expected to Boost Market Growth
Various government and private research organizations are increasingly engaged in research and development studies to increase the efficacy of ranitidine and examine possible potential of ranitidine to increase future scope of ranitidine market.
Furthermore, various clinical trials are currently undergoing to identify and compare efficacy between ranitidine and other proton pump inhibitors such as esomeprazole and rabeprazole to measure gastric acid reduction in stomach. With the result of these studies, the efficacy of ranitidine is expected to improve and offer better treatment regimes in reducing excessive gastric acid production in the near future.
Rising Cases of Various Gastric Ulcers and Digestive Diseases is expected to Increase Growth of the market
High prevalence of gastroesophageal reflux disease (GERD), intestinal & stomach ulcers, esophagitis, heartburn, and other digestive diseases due to unhealthy lifestyle, changing dietary patterns will lead to increase in demand for ranitidine-based medications in the near future. According to Florida Hospital, 2018 U.S. data statistics, in the U.S. over 60 million adults suffer from acid reflux symptoms every month. Furthermore, the source states that each day an estimated 25 million of the 60 million adults suffers from acid reflux symptoms. Also, according to the same source, about 20% of people with acid reflux will develop gastroesophageal reflux disease (GERD) in the near future.
Heartburn with or without regurgitation is identified as one of the prime symptoms of gastroesophageal reflux disease (GERD). According to World Gastroenterology Organization (WGO), 2015, prevalence of GERD is rapidly increasing worldwide, with differences reported in prevalence ranging from 2.5% to 6.6% in Eastern Asia while slightly higher up to 13.8% to 25.8% in North America.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ranitidine-market-2131
Key players operating in the global ranitidine market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Strides Pharma Science Limited (StridesShasun), Tocris Bioscience (R & D Systems), Merck KGaA, and Sun Pharmaceutical Industries Limited among others.
Detailed Segmentation:
Global Ranitidine Market, By Strength:
75 mg
150 mg
300 mg
Global Ranitidine Market, By Form:
Tablet
Syrup
Injection
Global Ranitidine Market, By Route of Administration:
Oral
Intravenous
Global Ranitidine Market, By Application:
Intestinal & Stomach Ulcers
Gastroesophageal Reflux Disease (GERD)
Esophagitis
Zollinger-Ellison Syndrome
Other Application
To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2131
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
PET-CT Scanner Device Market Growth Prospects Analysis - 2026
A positron emission tomography (PET) - computed tomography (CT) scan reveals information about both the structure and function of cells and tissues in the body during a single imaging session. In recent times, majority of PET scans are performed on instruments that are combined with PET and CT scanners. The combined PET-CT scans provide images that identify the anatomic location of abnormal metabolic activity within the body. The combined scans have been shown to provide more accurate diagnoses than the two scans performed separately.
The diagnosis of various diseases such as cancer, heart diseases, and certain brain disorders require the use of both PET and CT scans. PET scanners measure metabolic activity, whereas CT scanners highlight anatomical features. The risk to poor superimposition of separate imaging is reduced and the hybrid PET-CT process lessens burden on the patient by simplifying the scanning process. The use of PET-CT scanner hybrids combine the strengths of two well-established imaging modalities and helps in accurate diagnosis, localizing, and monitoring of the disease. Moreover, PET-CT scanners can record the images in extremely short time (less than a minute).
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2169
The global PET-CT scanner device market size was valued at US$ 1.9 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).
Increasing prevalence of chronic diseases and rising geriatric population is expected to drive the PET-CT scanner device market revenue
Rising prevalence of infectious and chronic diseases such as cancer and heart disease across the globe and increasing demand for effective diagnostic systems is expected to drive the PET-CT scanner market size. According to the National Centre for Health Statistics, 2011, heart disease is the leading cause of death in the U.S., killing over 600,000 people each year.
According to the International Agency for Research on Cancer (IARC), in 2012, an estimated 14.1 million new cancer cases were reported, globally. Among these, the most common form of cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%). According to the Centers for Disease Control and Prevention (CDC), February 2018 data, around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die due to liver cancer, every year in the U.S.
PET-CT Scanner Device Market - Regional Insights
On the basis of region, the global PET-CT scanner device market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global PET-CT scanner device market, owing to rising number of traumatic brain injury cases in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2013, around 282,000 people were diagnosed with brain injury and around 50,000 people died due to traumatic brain injury in the U.S. It is estimated to be a major cause of disability and death in the U.S.
Get Full Access of This Business Report @ https://www.coherentmarketinsights.com/market-insight/pet-ct-scanner-device-market-2169
PET-CT Scanner Device Market - Competitive Landscape
Key players operating in the global PET-CT scanner device market include General Electric Co., Hitachi, Ltd., Mediso Ltd., Koninklijke Philips N.V., PerkinElmer, Inc., Positron Corporation, Siemens AG, Shimadzu Corporation, Toshiba Corporation, and Yangzhou Kindsway Biotech Co. Ltd. Manufacturers are continually bringing in new PET/CT design. New technology enables more precise measurements of metabolic processes and data quantification, including assessment of cancerous tissue, neurologic disease, and cardiac blood flow (perfusion).
Detailed Segmentation:
Global PET-CT Scanner Device Market, By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
Global PET-CT Scanner Device Market, By Setting:
Fixed
Mobile
Global PET-CT Scanner Device Market, By Application:
Cardiology
Oncology
Neurology
Others
Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2169
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Ursodeoxycholic Acid Market Projections of Trends and Growth till 2026
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent progression of cystic fibrosis-related liver disorders. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover, it can improve long-term survival in patients with primary biliary cirrhosis.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2199
Significant improvement in liver health can be achieved through UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases.
The global ursodeoxycholic acid market size was valued at US$ 457.3 million in 2017 and is expected to exhibit a CAGR of 10.1% over the forecast period (2018 – 2026).
Increasing prevalence of gall stones and cystic fibrosis to propel the ursodeoxycholic acid market growth
Ursodeoxycholic acid is being increasingly used for treatment of chronic cholestatic liver diseases. Increasing prevalence of cystic fibrosis and gall stones is the major factor driving growth of the global ursodeoxycholic acid market during the forecast period. According to the Cystic Fibrosis Foundation 2015 data, around 30,000 people suffered from cystic fibrosis in the U.S. Moreover, around 1,000 new cases of cystic fibrosis are diagnosed in the country, annually. According to the American Gastroenterological Association 2017 report, gallstones is affecting 10-15% of the U.S. population annually, which accounts for around 25 million people.
Increasing research studies on ursodeoxycholic acid to bolster the market growth
Increasing research studies conducted on application of ursodeoxycholic acid (UDCA) in other disease indications is expected to fuel growth of the global ursodeoxycholic acid market. According to the University of Sheffield August 2018 study, UDCA improves mitochondrial dysfunction, which is known to be a causative factor for both sporadic and familial Alzheimer’s disease.
According to the Cure Parkinson’s Trust, U.K. 2018 article, researchers demonstrated that UDCA could protect dopamine cells grown in culture from apoptosis, or programmed cell death, by regulating a specific cell survival pathway.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ursodeoxycholic-acid-market-2199
Key Players
Major players operating in the global ursodeoxycholic acid market include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
Detailed Segmentation:
Global Ursodeoxycholic Acid Market, By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
Global Ursodeoxycholic Acid Market, By Mode of Extraction:
Synthetic
Biological
Global Ursodeoxycholic Acid Market, By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2199
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Nonalcoholic Steatohepatitis Treatment Market Report Explored in Latest Research to 2026
Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.
Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.
Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2279
Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.
The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).
Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue
Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.
According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279
Nonalcoholic Steatohepatitis Treatment Market - Regional Insights
On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.
Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape
Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
Detailed Segmentation:
Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2279
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Pipettes and Accessories Market Prospects and Growth Trends Analysis Till 2026
Pipettes are used in biotechnology, pharmaceutical, and chemical laboratories in order to transfer certain volume of liquids. Micropipettes are important in molecular biology experiments, which require microliter amounts of solutions whereas serological pipettes are used in microbiology laboratories to prepare cell cultures that require media preparations of milliliter volumes. Volume transfers with sterile cultures and solutions using instruments such as micropipettes and serological pipettes are one of several types of routine techniques performed in a laboratory. Pipette designs such as electronic pipetting, ultralight pipettes, plungers positions in more user-friendly configurations, and reducing frictional forces help in reducing strain.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2322
The global pipettes and accessories market size was valued at US$ 1.3 billion in 2017 and is expected to witness a CAGR of 4.0% over the forecast period (2018 – 2026).
Increasing prevalence of chronic constipation is expected to drive the pipettes and accessories market growth
Increasing research and development in the field of pharmaceuticals and biotechnology due to high prevalence of infectious diseases and cancer are the major factors driving the pipettes and accessories market growth. According to 2012 European Union Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world.
Pharmaceutical companies are increasingly focusing on conducting research and development activities as well as outsourcing such activities to academic and private research institutes. This in turn is increasing demand for liquid handling systems such as pipettes. Pharmaceutical companies are also increasingly outsourcing their research activities to privately-owned Contract Research Organizations (CRO) to maintain their presence in the growing pharmaceutical and biotechnology market.
Pipettes and Accessories Market - Regional Insights
On the basis of region, the global pipettes and accessories market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the largest market for biotechnology and pharmaceutical research and manufacturing and therefore, demand for pipettes and accessories is the highest in the region. According to a study published by the International Trade Administration in 2016, the U.S. is the major hub for drug manufacturing and is expected to grow considerably in future.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/pipettes-and-accessories-market-2322
Pipettes and Accessories Market - Competitive Landscape
Key players operating in the global pipettes and accessories market include, Thermo Fisher Scientific, Eppendorf AG, Hamilton Company, Mettler-Toledo International, Inc., Lab Depot Inc., Sartorius AG, BRAND GmbH + CO KG, Capp ApS, Corning Inc., Denville Scientific, Inc., Gilson, Inc., Greiner Bio-One International GmbH, Integra Biosciences AG, Kimble-chase, Nichiryo Co., Ltd., and Socorex ISBA SA.
Detailed Segmentation:
Global Pipettes and Accessories Market, By Product Type:
Manual Pipettes
Single-channel
Multi-channel
Electronic Pipettes
Single-channel
Multi-channel
Accessories
Buy Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2322
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Cardiac Rhythm Management Devices Market Scrutinized in New Research By 2026
Cardiac Rhythm Management (CRM) devices include pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. These devices perform various functions, including bradycardia pacing, cardiac resynchronization for heart failure, monitoring for arrhythmias, defibrillation, and anti-tachycardia pacing for tachyarrhythmia. Products such as cardiac resynchronization therapy can improve congestive heart failure symptoms by improving the timing of the heart’s contractions, resulting in pumping more blood to the body.
The global cardiac rhythm management devices market size was valued at US$ 19.05 billion in 2017, and is expected to witness a CAGR of 7.5% over the forecast period (2018 – 2026).
Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2364
Rising incidences of cardiac disorders worldwide is expected to drive the cardiac rhythm management devices market revenue
Rise in incidence of cardiovascular diseases such as cardiac arrhythmia, ischemic heart disease, and hypertension is expected to fuel growth of the cardiac rhythm management devices market. According to WHO report, in 2015, cardiovascular diseases was the leading cause of deaths accounting for 17.7 million deaths, worldwide.
Furthermore, technological advancements in cardiac rhythm management devices is the major growth rendering factor for the industry. For instance, adoption of advanced technologies in cardiac pacemakers such as pacemakers with improved battery life and MRI safe-pacemakers, delay the progression of persistent atrial fibrillation (AF) in patients suffering from bradycardia. These advancements are gaining significant traction and are expected to fuel the demand for cardiac rhythm management devices. For instance, in February 2017, Abbott received the Food and Drug Administration (FDA) approval for its MR-conditional labeling for Assurity MRI pacemaker and the Tendril MRI pacing lead.
Cardiac Rhythm Management Devices Market - Regional Insights
On the basis of region, the global cardiac rhythm management devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in global cardiac rhythm management devices market during the forecast period, due to increasing prevalence of cardiovascular diseases in the region. According to the American Heart Association (AHA), 2017, around 92.1 million adults in the U.S. are suffering from some form of cardiovascular disease or the after-effects of stroke. AHA report also stated that direct and indirect costs of cardiovascular diseases and stroke are estimated to account for US$ 316 billion, including health expenditures and lost productivity.
Cardiac Rhythm Management Devices Market - Competitive Landscape
Key players operating in the global cardiac rhythm management devices market include Medtronic plc. Abbott Laboratories, Abiomed, Boston Scientific Corporation, Biotronik Se Co Kg, Koninklijke Philips N.V., LivaNova Plc, Cardiac Science Corporation, Schiller Ag, and Zoll Medical Corporation.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/cardiac-rhythm-management-devices-market-2364
Detailed Segmentation:
Global Cardiac Rhythm Management Devices Market, By Product Type:
Cardiac Resynchronization Therapy Devices
- Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- Cardiac Resynchronization Therapy Pacemakers (CRT-P)
Defibrillator
- Implantable Cardioverter Defibrillators (ICDS)
- External Defibrillators
Pacemakers
- Single Chamber Pacemakers
- Dual Chamber Pacemakers
- Biventricular Pacemakers
Buy This Exclusive Report: https://www.coherentmarketinsights.com/insight/buy-now/2364
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Omeprazole Market Set to Encounter Paramount Growth Till 2026
Omeprazole is a commonly prescribed proton pump inhibitor (PPI) to reduce acidity. The drug is approved by the regulatory agencies for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD). Omeprazole is also used to promote healing of erosive esophagitis (esophageal damage caused by stomach acid).
Omeprazole is used in combination with antibiotics such as amoxicillin and clarithromycin for treating ulcers caused by the H. pylori bacteria.
The global omeprazole market size was valued at US$ 2,668.4 million in 2017, and is expected to exhibit a CAGR of 5.2% over the forecast period (2018 – 2026).
Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2380
Increasing prevalence of peptic ulcers is expected to propel omeprazole market growth
Increasing prevalence of duodenal ulcers is expected to propel growth of the omeprazole market. According to a survey by Virtual Medical Center, 2016, peptic ulcer is the most common disease occurring in about 10-15% of the global population at a time. It is common in men and more common in elderly people. The survey further stated that duodenal ulcers are four times more common than gastric ulcers.
Also, increasing awareness activities for the treatment of gastrointestinal disorders by various organizations is a major factor bolstering market growth. For instance, the International Foundation for Functional Gastrointestinal Disorders (IFFGD), a nonprofit education and research organization helps to improve the life of people affected by chronic digestive conditions. IFFGD enhances awareness, supports research, for treating gastrointestinal disorders and educate individuals.
Increasing prevalence of H.pylori associated infection and favorable pricing policies to bolster the market growth
North America is expected to hold a dominant position in the global omeprazole market. This is owing to increasing number of people affected by H.pylori infection, which in turn is expected to increase the risk of gastric and duodenal ulcers. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Health Information Center, 2014, about 30 to 40 percent of people in the U.S. suffer from the H. pylori infection, thus increasing the risk of duodenal and gastric development.
Key Players
Major players operating in the global omeprazole market include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc, Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.
Detailed Segmentation:
Global Omeprazole Market, By Dosage Form:
Capsule
Powder
Tablet
Global Omeprazole Market, By Indication:
Duodenal Ulcer
Gastric Ulcer
Gastroesophageal Reflux Disease (GERD)
Erosive Esophagitis
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Central Venous Catheter Market to Record an Impressive Growth Rate by 2026
Central venous catheters play a major role in modern healthcare, as they allow easy administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as provide hemodialysis access and hemodynamic monitoring.
The global central venous catheter market size was valued at US$ 1,167.4 million in 2017, and is expected to exhibit a CAGR of 6.2% over the forecast period (2018 – 2026).
Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2400
Increasing prevalence of cancer and renal diseases is expected to propel growth of central venous catheter market
Central venous catheterization is used for chemotherapy administration, total parenteral nutrition, administration of intravenous fluids, administration of blood and platelet transfusions, and other uses. High prevalence of cancer is expected to propel demand for central venous catheterization, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.
Similarly, according to the study by University of California, 2014, around 2 million people worldwide are affected by end stage renal disease (ESRD) and the number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually.
Increasing adoption of central venous catheters in North America is expected to bolster the market growth
North America holds dominant position in the global central venous catheter market, owing to high availability of catheters in medical settings. According to the survey by PavMed, 2016, around 7 million central vascular access devices are utilized annually in the U.S., which includes 400-500,000 implantable ports. Increasing prevalence of cancer in the region is also expected to boost the market growth. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.
Moreover, increase in central venous infections is expected to enhance demand for novel antimicrobial catheters, thereby reducing economic burden caused due to hospitalization. For instance, according to the Cincinnati Children’s Hospital Medical Center, 2014, around 250,000 central venous catheter infections occur annually, procuring the total cost of US$ 7.5- 11 Bn annually to the U.S. healthcare system.
Key Players
Major players operating in the global central venous catheter market include, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation.
Detailed Segmentation:
Global Central Venous Catheter Market, By Product Type:
Peripherally Inserted Central Catheters (PICC)
Implantable Ports
Tunneled Central Venous Catheter
Non-tunneled Central Venous Catheter
Global Central Venous Catheter Market, By Design:
Single Lumen
Double Lumen
Multiple Lumen
Global Central Venous Catheter Market, By Composition:
Polyurethane
Polyethylene
Silicon
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/central-venous-catheter-market-2400
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Stem Cell Cartilage Regeneration Market to Reflect Steady Growth Rate by 2026
Stem cells therapy are emerging as an important therapeutic option in the field of cartilage regeneration. Rapid development of stem cell-based therapy for cartilage regeneration in the recent past has been witnessed across the world. Stem cells are mainly classified in three kinds of cells: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.
The global stem cell cartilage regeneration market size was valued at US$ 254.4 million in 2017, and is expected to witness a CAGR of 8.9% over the forecast period (2018 – 2026).
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2448
Increasing Adoption of Minimally Invasive Surgery Procedures is expected to Drive Growth of Stem Cell Cartilage Regeneration Market
Stem cell therapy for knees, minimally invasive procedure, has the potential to decrease inflammation, halt progression of arthritic damage, repair joint cartilage, and delay or avoid knee replacement surgery. Injection of progenitor cells, especially mesenchymal stem cells (MSCs), has been found to be an effective and better solution for repairing degenerative cartilage compared to implantation of differentiated cells such as articular cartilage.
In addition to this, other potential benefits such as lower risk and shorter duration of minimally invasive surgery procedures are expected to fuel demand for stem cell therapy for cartilage regeneration during the forecast period. For instance, according to NCBI 2016 report, a minimally invasive procedure to harvest stem cells from both fat and bone marrow and inject the concentrated cells under image guidance can be performed in 2-3 hours.
Stem Cell Cartilage Regeneration Market - Regional Insights
On the basis of region, the global stem cell cartilage regeneration market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the most conducive region for growth of the stem cell cartilage regeneration market over the forecast period, due to high presence of key players in the region. Key players such as Vericel Corporation, Osiris Therapeutics, among others are focusing on various growth strategies such as gaining regulatory product approvals and launching innovative stem cell based cartilage regeneration products and technologies in the market.
Stem Cell Cartilage Regeneration Market - Competitive Landscape
Key players operating in the global stem cell cartilage regeneration market include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
Detailed Segmentation:
Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs)
Global Stem Cell Cartilage Regeneration Market, By Treatment:
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/stem-cell-cartilage-regeneration-market-2448
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Pemetrexed Market Size Will Escalate Rapidly in the Near Future
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2458
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.
For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.
For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.
North America is expected to Hold Dominant Position, Owing to High Prevalence of Non-small Cell Lung Cancer and its High Treatment Rate in the U.S.
According to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed) generated around 50% of its revenue from the U.S. Hence, North America is expected to be most conducive region for growth of the pemetrexed market, due to high prevalence of non-small cell lung cancer and high cost for its treatment.
For instance, according to the data published by the American Cancer Society in 2017, lung cancer (both small cell and non-small cell) is the second most common type of cancer in U.S and around 13% of all new cancers are lung cancer.
American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) would be diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage IIIA NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.
Detailed Segmentation:
Global Pemetrexed Market, By Strength :
100 mg
500 mg
Global Pemetrexed Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Hemophilia Gene Therapy Market Size Projected to be Resilient by 2026
Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patient’s body.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2480
The global hemophilia gene therapy market was valued at US$ 0.00 million in 2017 and is expected to witness a CAGR of 56.0% over the forecast period (2018 – 2026).
Increasing hemophilia patient base worldwide especially in developed countries is expected to drive growth of the hemophilia gene therapy market
High prevalence of hemophilia is increasing demand for sustainable treatment of the disease, which is projected to drive the market growth over the forecast period. According to the National Hemophilia Foundation factsheet 2018, hemophilia affected over 400,000 individuals worldwide. Moreover, according to same source, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. According to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.
Strong gene-based product pipeline for hemophilia treatment is expected to drive the hemophilia gene therapy market growth
Gene therapy for hemophilia has strong product pipeline, which is expected to enter the market in the near future. This is expected to drive the market growth, as it would result in availability of new treatment options for management of hemophilia. By Januarys 2019, over 15 investigational gene therapy are under the clinical development stage. In December 2018, Spark Therapeutics announced updated preliminary data for the ongoing phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A.
Current therapies for treating hemophilia are only symptomatic management of the disease by administering clotting factors XIII or IX. Furthermore, there are serious adverse effects associated with plasma derived products, and limited access to treatment. Gene therapy may address these issues to certain level. BioMarin Pharmaceutical’s gene therapy product Valoctocogene roxaparvovec for hemophilia A is in phase III of clinical development in 2019.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are supporting the product development for gene therapy by allotting breakthrough designation status to investigational gene therapy. For instance, in 2017, the U.S. FDA granted breakthrough therapy designation to valoctocogene roxaparvovec, which is an Adeno -associated virus 5 factor VIII vector designed to restore factor VIII plasma concentrations in patients with hemophilia A.
Key players operating in the global hemophilia gene therapy market include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., and Freeline Therapeutics.
Detailed Segmentation:
Global Hemophilia Gene Therapy Market, By Type:
Hemophilia A
Hemophilia B
Global Hemophilia Gene Therapy Market, By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Look Insights Of Global Hemophilia Gene Therapy Market Research Report At https://www.coherentmarketinsights.com/market-insight/hemophilia-gene-therapy-market-2480
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Neuroscience Market Release Latest Trends and Industry Vision 2026
Neuroscience involves use of various methods to measure and image the brain activity. Neuroscience is umbrella term focusing on molecular, cellular, developmental, structural, functional, evolutionary, computing, psychosocial, and medical aspects of the nervous system. Research in neuroscience is constantly evolving based on biology, pharmaceutical science, medicine, cognitive science, and biomedical engineering. Neuroscience-based devices help in collecting valuable information regarding activities in brain and can be used in various areas such as better understanding of pathophysiology and symptoms of various chronic neurological diseases such as epilepsy, Alzheimer’s disease and other dementias; cerebrovascular diseases including stroke, migraine, and other headache disorders, multiple sclerosis, Parkinson's disease, neuro-infections, brain tumors; and traumatic disorders of the nervous system due to head trauma.
Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2487
These devices consist of different instruments that are required for neuroscience-based experiments. Various types of electrophysiology instruments and imaging instruments are utilized to map the brain and examine the brain activity.
The global neuroscience market size was valued at US$ 26,593 million in 2017, and is expected to witness a CAGR of 3.9% over the forecast period (2018 – 2026).
Increasing burden of neurological diseases worldwide is expected to be a major factor accelerating the growth of the global neuroscience market
Increasing prevalence of various chronic neurological diseases worldwide is expected to be a major driver for growth of the global neuroscience market. This is owing to high unmet medical need in terms of timely diagnosis and effective treatment of neurological diseases. This in turn requires better understanding of pathophysiology of the diseases and improvement in knowledge about functioning of nervous system, which is expected to boost demand for neuroscience devices.
According to World Alzheimer Report in 2016, around 46.5 million people suffered from Alzheimer’s disease and the number was expected to reach 50 million by 2017, with a frequency of one new patient of Alzheimer’s disease every there seconds worldwide.
According to World Health Organization (WHO) 2016 report, around 6 million deaths occur due to stroke, annually and over 80% of these deaths take place in low- and middle-income countries. Moreover, over 50 million people suffer from epilepsy and 47.5 million people from dementia, with 7.7 million new cases, annually worldwide.
Increasing product launch and government funding for neuroscience research is expected to propel the neuroscience market growth
Key players in the market are focused on launching new instruments and software components, which address current research needs for neuroscience. This in turn is expected to boost the market growth. For instance, in 2015, Blackrock Microsystems LLC showcased new digital, wireless brain-interface titled — CerePlex W – at Society for Neuroscience Conference (SfN), Washington, U.S.
Key players operating in the global neuroscience market include, Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Scientifica Ltd., Blackrock Microsystems LLC, Femtonics Ltd., LaVision Biotec GmbH, Intan Technologies, NeuroNexus Technologies, Inc., Newport Corporation, Neuralynx Inc., Plexon Inc., Mediso Medical Imaging Systems, Noldus Information Technology, Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.
Detailed Segmentation:
Global Neuroscience Market, By Component:
Instrument
Software
Services
Global Neuroscience Market, By End User:
Hospitals
Diagnostic Laboratories
Research Institutes
Academic Institutes
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/neuroscience-market-2487
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Minimally Invasive Surgical Instrument Market Necessity And Demand to 2026
Minimally invasive surgical instruments are used in minimally invasive surgeries (MIS). These surgeries are performed to limit the size and number of cuts and incisions to lessen the wound healing time. These surgeries, reduce hospital stay with less pain and few complications. Minimally invasive surgeries are preferred by majority of people due to its benefits. Different type of instruments are used in minimally invasive such as small tubes, compact cameras, catheters, and others. Minimally invasive surgeries are widely conducted in cosmetology, as it involves minimum scarring and quick healing. Another type of minimally invasive surgery is robotic surgery. It provides a magnified, 3-D view of the surgical site and helps the surgeon to operate with precision, flexibility, and control.
Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2526
The global minimally invasive surgical instruments market size was valued at US$ 12,878.3 million in 2017, and is expected to witness a CAGR of 6.1% over the forecast period (2018 – 2026).
Increasing numbers of minimally invasive surgeries is expected to drive growth of the minimally invasive surgical instrument market
Increasing number of minimally invasive surgeries is major driving factor for growth of the minimally invasive surgical instruments market revenue, as minimally invasive surgeries are less painful, cost effective, and reduces hospital stay. According to Healthcare Cost and Utilization Project (HCUP) in 2014, around 11.4 million outpatient surgeries were performed in the U.S. Most performed minimally invasive surgeries are cholecystectomy, colectomy, heart surgery, kidney surgery, etc.
Furthermore, minimally invasive surgical instruments are widely used in cosmetic surgeries. According to American Society of Plastic Surgeons (ASPS), around 15.7 million minimally invasive cosmetic procedures were performed in 2017.
Minimally Invasive Surgical Instrument Market - Regional Insights
On the basis of region, the global minimally invasive surgical instruments market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global minimally invasive surgical instruments market during the forecast period, owing to high prevalence of chronic disorders such as heart disease, cancer, and diabetes, which require the minimally invasive surgery. According to American Association of Retired Persons Chronic Conditions 2018, reports around 45% or 133 million of American’s population suffer from at least one chronic disease.
Minimally Invasive Surgical Instrument Market - Competitive Landscape
Key players operating in the global minimally invasive surgical instrument market include Medtronic Plc, Ethicon Inc., Aesculap Inc., Stryker Corporation, B. Braun Melsungen Ag and Smith & Nephew Plc. Other players in this market include ConMed Corporation, Abbott Laboratories, Applied Biomedical Resources Corporation, Boston Scientific Corporation, Microline Surgical, Alcon Laboratories Inc., and Zimmer Biomet Holdings Inc.
Detailed Segmentation:
Global Minimally Invasive Surgical Instrument Market, By Product Type:
Handheld Instruments
Electrosurgical Instruments
Guiding Devices
Inflation Systems
Monitoring and Visualization Devices
Global Minimally Invasive Surgical Instrument Market, By Application:
Cosmetic Surgery
Urology
Gynecology
Ophthalmology
Gastrointestinal Surgery
Cardiovascular Surgery
Respiratory Surgery
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/minimally-invasive-surgical-instrument-market-2526
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
